In its May 10 Obesity Market Intelligence newsletter, the disease forecasting company said the number of atrial fibrillation cases linked to obesity are predicted to grow from 2.92 million to 3.83 million in the U.S. by 2023. Weight loss interventions, such as Zepbound (tirzepatide), could change this figure.
An Eli Lilly clinical trial found obese and overweight adults lost, on average, 22.5% of their body weight after 72 weeks on Zepbound. Airfinity ran 10,000 simulations on Zepbound’s effects on body weight and atrial fibrillation outcomes, and the company’s forecast has an assumption of 100% medication adherence. The analysts predict Zepbound could reduce atrial fibrillation prevalence by 16.4%, or stave off 627,000 cases.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
